MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Pioglitazone hydrochloride

CAS No. : 112529-15-4

MCE 站：Pioglitazone hydrochloride

产品活性：Pioglitazone 是一种有效，选择性的 PPARγ 激动剂，高亲和力结合到 PPARγ 配体结合域。作用于人和鼠 PPARγ，EC₅₀ 分别为 0.93 和 0.99 μM。

研究领域：Cell Cycle/DNA Damage  |  Apoptosis

作用靶点：PPAR  |  Ferroptosis

In Vitro: AGEs-induced beta cell necrosis is completely abrogated by adding Pioglitazone to the AGEs culture medium. Furthermore Pioglitazone completely prevented any AGEs-induced increment in caspase-3 activation, thereby restoring caspase-3 activity to the same levels as the control cells. As expected AG is able to counteract AGEs-induced impaired viability.

In Vivo: The serum-free fatty acid and triglyceride levels as well as adipocyte sizes in ob/ob and adipo^-/- ob/ob mice are unchanged after 10 mg/kg Pioglitazone but are significantly reduced to a similar degree after 30 mg/kg Pioglitazone. Moreover, the expressions of TNFα and resistin in adipose tissues of ob/ob and adipo^-/- ob/ob mice are unchanged after 10 mg/kg Pioglitazone but are decreased after 30 mg/kg Pioglitazone. Thus, Pioglitazone-induced amelioration of insulin resistance and diabetes may occur adiponectin dependently in the liver and adiponectin independently in skeletal muscle. Pioglitazone (10 mg/kg per d) treatment significantly attenuates the loss of body weight (BW) and cardiac hypertrophy. Pioglitazone treatment significantly reduces the elevated serum glucose levels and markedly improved the associated dyslipidemia. Furthermore, there is a slight but significant increase in serum creatinine level in D rats over their N controls (P <0.05). However, a marked renal dysfunction is observed in diabetic nephropathic (DN) group (P<0.05). Moreover, DN rats exhibits the highest serum activity of CK-MB, relative to both N and D rats (P<0.05). Pioglitazone is able to decrease the elevated serum levels of both creatinine and creatine kinase-MB (CK-MB).

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Apoptosis Compound Library  |  Cell Cycle/DNA Damage Compound Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  Anti-Aging Compound Library  |  Drug Repurposing Compound Library  |  Diabetes Related Compound Library  |  Ferroptosis Compound Library  |  Anti-COVID-19 Compound Library  |  NMPA-Approved Drug Library  |  Orally Active Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Erastin  |  Ferrostatin-1  |  Cisplatin  |  Cycloheximide  |  RSL3  |  Acetylcysteine  |  Deferoxamine mesylate  |  SP600125  |  Necrostatin-1  |  Retinoic acid  |  Rosiglitazone  |  SB 202190  |  GW9662  |  Curcumin  |  Hemin  |  (-)-Epigallocatechin Gallate  |  TBHQ  |  Simvastatin  |  Bardoxolone methyl  |  U-73122  |  Pifithrin-α hydrobromide  |  Lovastatin  |  Trolox  |  Eprenetapopt  |  L-Glutathione reduced  |  GW6471  |  Pioglitazone  |  Deferiprone  |  NADPH tetrasodium salt  |  Artesunate

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。